Physiological and Ecological impact of pre- and probiotic interventions in relation to food allergy in early-life

The co-evolution of man and microbiota has diversified the nutrients compatible with human digestion and thus survival. The increased fitness obtained from a better access to food has favored the development of mechanisms able to protect and preserve microbiota diversity, such as barrier function and host immunity.

Man consumes more than 50000L of liquid and 30 tons of food in a lifetime. Nutrients therefore constitute a major environmental exposure to man, which can both protect from as well as lead to malnutrition, obesity, allergy etc. It is likely that the impact of nutrients on physiopathology are mediated by alterations in barrier function and host immunity. Here we propose to evaluate the effects of pre- and probiotics administered to pregnant women and their child in early-life.

The effect will be assessed clinically (food allergy) and associated with measures of barrier function and host immunity. The consortium of 5 partners will evaluate clinical outcome, humoral and cellular host immunity as well as microbiota ecology in feces and breastmilk. We expect to observe alterations of gut microbiota ecology associated with modifications of host immunity to commensal microbes caused by nutritional interventions with pre- and probiotics. We hope to be able to support the transition to healthy food alternatives, which could reduce risk of developing food allergy in early-life.


Partner Organization
Partner Country
National Research Institute for Agriculture, Food and Environment (INRAE), Unite Biopolymères Interactions Assemblages. France
Technical University of Munich (TUM), TUM School of Life Sciences Germany
Dept. of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev (BGU) Israel
Spanish National Research Council (CSIC), Instituto de Agroquímica y Tecnología de Alimentos. Spain


Project number:
Duration: 76%
Duration: 76 %
Related funding round:
Project lead and secretary:
Martin Larsen
Responsible organisation:
Inserm, France